On September 30, 2026, the United States Court of Appeals for the Third Circuit revived a putative securities fraud class action against Ocugen, Inc., a small, publicly traded pharmaceutical company, holding that a stock’s rapid price recovery after a corrective disclosure cannot, on its own, prove that an earlier misstatement was immaterial. In re Ocugen, Inc. Securities Litigation, No. 25-2653 (3d Cir. Sept. 30, 2026). The decision abrogates what the court itself labeled the “Oran-Burlington rule,” a line of Third Circuit precedent stretching back nearly 30 years. For practitioners defending or bringing Section 10(b) claims in Pennsylvania, New Jersey, or Delaware federal courts, the ruling removes a familiar tool from the motion-to-dismiss toolkit and replaces it with a more fact-intensive materiality inquiry.






